OCUL vs TGT · rev $24.3M vs P/E 17, rev $51.98B
Ocular Therapeutix Inc (OCUL) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on US.
Target Corporation (TGT) is a discount stores company listed on NYSE. It is led by Michael J. Fiddelke.
Latest reported OCUL revenue for 2026-06-30 was $24.3M. Net income was -$167.4M. OCUL currently screens at market cap $1.76B.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
OCUL currently screens at market cap $1.76B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the OCUL and TGT stock pages for the full models.
Not investment advice.